Thermo Fisher's Proteomics Tech Uncovers 2,500 New Genetic-Protein…

Event summary

Thermo Fisher's collaboration with PRECISE and NTU Singapore identified 2,500 previously unreported genetic-protein associations from 10,000 participant samples.
The study combined Thermo Fisher’s Olink® PEA platforms with Orbitrap™ Astral™ mass spectrometry and Seer’s Proteograph® Product Suite.
Findings were presented at the HUPO World Congress, highlighting the integration of proteomics technologies with genomic and health data.
The PRECISE-SG100K study aims to improve understanding of disease biology in Singapore’s diverse Asian population.

The big picture

Thermo Fisher’s collaboration underscores the growing importance of integrating proteomics and genomics data to uncover new biological insights. The study’s focus on Singapore’s diverse population addresses a critical gap in biomedical research, potentially expanding the applicability of precision medicine. With annual revenue exceeding $45 billion, Thermo Fisher is well-positioned to capitalize on these advancements, reinforcing its leadership in serving science.

What we're watching

Data Integration: How Thermo Fisher will leverage the 2,500 new genetic-protein associations to prioritize biological pathways for biomarker and therapeutic research.
Technological Synergy: Whether the combination of Olink® PEA and Orbitrap™ Astral™ mass spectrometry can sustain its complementary advantages in large-scale proteomics studies.
Diverse Population Insights: The pace at which insights from Singapore’s multi-ethnic population will translate into broader precision medicine applications globally.